Pharmaceutical Technology
October 02, 2001
Contract Services
25
10
Recovery of the contract services industry picked up steam in the quarter ending 30 June 2001.
October 02, 2001
Articles
25
10
The authors provide a systematic evaluation of the effects of solvent systems, PEG molecular weight, and concentration of CA to PEG on the thermomechanical properties and permeabilities of CA-free films.
October 02, 2001
Articles
25
10
Two types of hydrogels used in parenteral protein-delivery systems offer opportunities for achieving a variety of prolonged- and delayed-release patterns.
October 02, 2001
Columns
25
10
NIR quality control technology, relatively new to the pharmaceutical industry, could revolutionize processing and packaging.
October 02, 2001
Columns
25
10
FDA may adopt new requirements to enhance the safe use of pharmaceuticals and ensure that all US drugs are available when needed.
October 02, 2001
Articles
25
10
Testing of an in situ fiber-optic transmission probe demonstrates sound hydrodynamic performance and reduced stray-light limitations.
October 02, 2001
Articles
25
10
Insulin is one of the most popular proteins to be studied for oral delivery. The authors review the current status of the development strategies of insulin drug delivery systems, the various challenges associated with these systems, and how these challenges may be overcome.
October 02, 2001
Articles
25
10
A summary of the conclusions of the PhRMA Workshop on Acceptable Analytical Practices describes equipment qualification practices and guidelines that are designed to help the pharmaceutical industry be consistent in meeting core requirements.
October 02, 2001
Articles
25
10
In Part I of this article, the authors summarize the principles of various integrity tests, including their performance and purpose.
October 02, 2001
Contract Services
25
10
Evaluating a CRO should involve acquiring feedback from various personnel within the CRO, ranging from executives to line workers.
October 02, 2001
Contract Services
25
10
The author proposes a strategy for achieving a successful partnership with Big Pharma on the basis of forming a relationship with the company, deliberately managing the alliance, and clearly defining roles and responsibilities.